OS Therapies, Inc. (OSTX) Press Releases https://ir.ostherapies.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/ostherapies/files/theme/images/logo-sm-2x.png OS Therapies, Inc. Logo Equisolve Investor Relations Suite <![CDATA[OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial]]> https://ir.ostherapies.com/news-events/press-releases/detail/126/os-therapies-achieves-statistically-significant-benefit-for Tue, 08 Sep 26 06:00:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/126/os-therapies-achieves-statistically-significant-benefit-for <![CDATA[OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance]]> https://ir.ostherapies.com/news-events/press-releases/detail/125/os-therapies-provides-ost-her2-metastatic-osteosarcoma Wed, 02 Sep 26 07:20:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/125/os-therapies-provides-ost-her2-metastatic-osteosarcoma <![CDATA[OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates]]> https://ir.ostherapies.com/news-events/press-releases/detail/124/os-therapies-reports-second-quarter-2026-financials-and Mon, 17 Aug 26 07:40:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/124/os-therapies-reports-second-quarter-2026-financials-and <![CDATA[OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma]]> https://ir.ostherapies.com/news-events/press-releases/detail/123/os-therapies-granted-u-s-fda-type-c-statistical-methods Thu, 13 Aug 26 08:45:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/123/os-therapies-granted-u-s-fda-type-c-statistical-methods <![CDATA[OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program]]> https://ir.ostherapies.com/news-events/press-releases/detail/122/os-therapies-accepts-new-fda-meeting-request-to-review Wed, 08 Jul 26 09:00:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/122/os-therapies-accepts-new-fda-meeting-request-to-review <![CDATA[OS Therapies Third Quarter 2026 Corporate Outlook]]> https://ir.ostherapies.com/news-events/press-releases/detail/121/os-therapies-third-quarter-2026-corporate-outlook Mon, 06 Jul 26 09:00:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/121/os-therapies-third-quarter-2026-corporate-outlook <![CDATA[OS Therapies Appoints Dr. Craig Eagle to Board of Directors]]> https://ir.ostherapies.com/news-events/press-releases/detail/120/os-therapies-appoints-dr-craig-eagle-to-board-of-directors Thu, 02 Jul 26 07:30:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/120/os-therapies-appoints-dr-craig-eagle-to-board-of-directors <![CDATA[OS Therapies Provides U.S. Regulatory Update]]> https://ir.ostherapies.com/news-events/press-releases/detail/119/os-therapies-provides-u-s-regulatory-update Tue, 30 Jun 26 07:40:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/119/os-therapies-provides-u-s-regulatory-update <![CDATA[OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma]]> https://ir.ostherapies.com/news-events/press-releases/detail/118/os-animal-health-announces-peer-reviewed-publication-of Fri, 26 Jun 26 07:40:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/118/os-animal-health-announces-peer-reviewed-publication-of <![CDATA[OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma]]> https://ir.ostherapies.com/news-events/press-releases/detail/117/os-therapies-achieves-global-regulatory-alignment-on-design Mon, 08 Jun 26 06:00:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/117/os-therapies-achieves-global-regulatory-alignment-on-design